Know Cancer

forgot password

Phase II Study of BAY 43-9006 (NSC #724772) as Single Agent in Unresectable or Metastatic Gallbladder Carcinoma and Cholangiocarcinoma

Phase 2
Not Enrolling
Adenocarcinoma of the Extrahepatic Bile Duct, Adenocarcinoma of the Gallbladder, Adenocarcinoma With Squamous Metaplasia of the Gallbladder, Cholangiocarcinoma of the Extrahepatic Bile Duct, Cholangiocarcinoma of the Gallbladder, Recurrent Extrahepatic Bile Duct Cancer, Recurrent Gallbladder Cancer, Squamous Cell Carcinoma of the Gallbladder, Unresectable Extrahepatic Bile Duct Cancer, Unresectable Gallbladder Cancer

Thank you

Trial Information

Phase II Study of BAY 43-9006 (NSC #724772) as Single Agent in Unresectable or Metastatic Gallbladder Carcinoma and Cholangiocarcinoma


I. To assess the objective response probability (complete responses and partial responses)
for BAY 43-9006 in patients with unresectable or metastatic gallbladder or

II. To assess overall survival, time to treatment failure and progression-free survival in
these patients.

III. To assess quantitative and qualitative toxicities of this regimen. IV. To evaluate in a
preliminary fashion relevant prognostic and predictive molecular markers of clinical outcome
in gallbladder and cholangiocarcinoma.

OUTLINE: This is a multicenter study.

Patients receive oral sorafenib twice daily on days 1-28. Courses repeat every 28 days in
the absence of disease progression or unacceptable toxicity.

After completion of study treatment, patients are followed every 6 months for 3 years.

Inclusion Criteria:

- Patients must have a cytologically or pathologically confirmed diagnosis of
cholangiocarcinoma or gallbladder carcinoma

- The pathologic confirmation of gallbladder or cholangiocarcinoma may be made
from the primary or metastatic site; biopsy of the gallbladder or bile duct mass
is not necessary; patients with pathologic confirmation of adenocarcinoma of a
metastatic site, along with clinical documentation of gallbladder or bile duct
involvement and no evidence of another primary are also eligible; if clinical
documentation of gallbladder or bile duct involvement is not possible because of
removal of the organ, a clinically and/or radiographically consistent picture
plus pathologic findings from the metastatic site that are determined to be
consistent with cholangiocarcinoma are acceptable

- Eligible pathologic type: Patient must have one of the following subtypes:
adenocarcinoma NOS, papillary carcinoma, adenocarcinoma, intestinal type, clear
cell adenocarcinoma, mucinous adenocarcinoma, signet ring cell carcinoma,
squamous cell carcinoma, adenosquamous carcinoma, small cell carcinoma,
undifferentiated carcinoma, carcinoma NOS; patient must not have carcinoid
tumors or sarcomas

- Patient must have locally advanced or distant metastatic disease that is not
surgically curable

- Patient must have measurable disease; x-rays, scans or physical examinations used for
tumor measurement must have been completed within 28 days prior to registration;
x-rays, scans or other tests for assessment of non-measurable disease must have been
performed within 42 days prior to registration; all disease must be assessed

- Institutions are required to submit paraffin-embedded specimens

- Institutions are required to seek additional patient consent for submission of blood

- Patient may have had prior surgery, including surgery for their gallbladder or
cholangiocarcinoma; patients must be at least 14 days beyond any major surgery, and
recovered from all effects of surgery

- Patient must not have received prior therapy for unresectable or metastatic disease;
patient may have received prior chemotherapy, hormonal therapy, immunotherapy,
radiation therapy (to less than 25% of bone marrow only) or chemoradiotherapy as
neoadjuvant or adjuvant treatment; this must have been completed at least 12 months
prior to documented recurrence or metastatic disease; patient must have recovered
from all radiation induced toxicities

- Prior radiation therapy to metastatic sites, such as bone, is allowed as long as the
patient has measurable lesion(s) that were not treated with radiation therapy; at
least 28 days must have elapsed since completion of radiation therapy, and patient
must have recovered from all effects

- Patient must not have received prior BAY 43-9006 or any inhibitor of VEGFR or the
MAPK pathway

- Patient must have Zubrod performance status of 0-1

- Total serum bilirubin =< 3 x the institutional upper limit of normal (IULN)

- Serum transaminase (SGOT or SGPT) =< 2.5 x IULN; if liver metastasis is present, SGOT
or SGPT must be =< 5 x IULN

- Patients with biliary obstruction must have decompressions of the biliary tree by
ERCP and stenting or percutaneous drainage

- Serum creatinine =< 1.5 x IULN OR measured creatinine clearance >= 60 mL/min OR
estimated creatinine clearance >= 60 mL/min

- Leukocyte count >= 3,000/mcL

- ANC >= 1,000/mcL

- Platelets >= 100,000/mcL

- PT, INR and PTT =< IULN

- Patients must not be taking the cytochrome P450 enzyme-inducing antiepileptic drugs
(phenytoin, carbamazepine, and Phenobarbital), rifampin, or St. Johns Wort

- Patient must not be on therapeutic anticoagulation; prophylactic anticoagulation
(i.e., low dose warfarin) of venous or arterial access devices is allowed provided
that the requirements for PT, INR and PTT are met

- Patient must not have any evidence of bleeding diathesis

- Patients must not have clinically significant cardiac disease that is not well
controlled by medication (e.g., congestive heart failure, symptomatic coronary artery
disease and cardiac arrhythmias) or myocardial infarction within 12 months prior to

- Patient must not have uncontrolled hypertension

- Patient must not have known brain metastases because of their poor prognosis and
because they often develop progressive neurologic dysfunction that would confound the
evaluation of neurologic and other adverse events

- Patient must either be able to swallow and/or receive enteral medications via
gastrostomy feeding tube; tablets must not be crushed; patient must have the ability
to absorb medication (i.e., no malabsorption syndrome); patient must not have
intractable nausea or vomiting

- Patient must have no plans to receive concurrent chemotherapy, hormonal therapy,
radiotherapy, immunotherapy or any other type of therapy for treatment of cancer
while on this protocol; radiation for palliation to metastatic sites is allowed as
long gas the target lesions are not irradiated

- Women/men of reproductive potential must agree to use an adequate contraception
(hormonal or barrier method of birth control or abstinence) prior to study entry and
for the duration of protocol treatment; post-menopausal women must be amenorrheic for
at least 12 months to be considered of non-childbearing potential; pregnant or
nursing women are not eligible for this protocol; should a woman become pregnant or
suspect she is pregnant while participating in this study, she should inform her
treating physician immediately; breastfeeding must be discontinued if the mother is
treated with BAY 43-9006

- HIV-positive patients must have a CD4 count > 500 and must have no active
opportunistic infection; in addition, patient must not be receiving combination
anti-retroviral therapy

- No other prior malignancy is allowed except for the following: adequately treated
basal cell or squamous cell skin cancer, in situ cervical cancer, adequately treated
stage I or II cancer from which the patient is currently in complete remission, or
any other cancer from which the patient has been disease free for five years

- If day 14, 28 or 42 falls on a weekend or holiday, the limit may be extended to the
next working day

- In calculating days of tests and measurements, the day a test or measurement is
done is considered day 0; therefore, if a test is done on a Monday, the Monday
two weeks later would be considered day 14; this allows for efficient patient
scheduling without exceeding the guidelines

- All patients must be informed of the investigational nature of this study and must
sign and give written informed consent in accordance with institutional and federal

- At the time of patient registration, the treating institution's name and ID number
must be provided to the Data Operations Center in Seattle in order to ensure that the
current (within 365 days) date of institutional review board approval for this study
has been entered into the data base

Type of Study:


Study Design:

Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment

Outcome Measure:

Response probability (confirmed complete and confirmed partial responses)

Outcome Time Frame:

Up to 3 years

Safety Issue:


Principal Investigator

Anthony El-Khoueiry

Investigator Role:

Principal Investigator

Investigator Affiliation:

Southwest Oncology Group


United States: Food and Drug Administration

Study ID:




Start Date:

October 2005

Completion Date:

Related Keywords:

  • Adenocarcinoma of the Extrahepatic Bile Duct
  • Adenocarcinoma of the Gallbladder
  • Adenocarcinoma With Squamous Metaplasia of the Gallbladder
  • Cholangiocarcinoma of the Extrahepatic Bile Duct
  • Cholangiocarcinoma of the Gallbladder
  • Recurrent Extrahepatic Bile Duct Cancer
  • Recurrent Gallbladder Cancer
  • Squamous Cell Carcinoma of the Gallbladder
  • Unresectable Extrahepatic Bile Duct Cancer
  • Unresectable Gallbladder Cancer
  • Adenocarcinoma
  • Adenocarcinoma, Mucinous
  • Carcinoma
  • Carcinoma, Squamous Cell
  • Metaplasia
  • Gallbladder Neoplasms
  • Bile Duct Neoplasms
  • Cholangiocarcinoma



Southwest Oncology Group San Antonio, Texas  78245